Ipca Laboratories Limited
IPCALAB
Peringkat dalam Saham
#3405
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Harga Saham
$20.02
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$5.08B
Perubahan (1 hari)
-1.65%
Perubahan (1 tahun)
38.46%
Negara
IN
Perdagangan Ipca Laboratories Limited (IPCALAB)
Kategori
Healthcare
Laba untuk Ipca Laboratories Limited (IPCALAB)
Laba pada Jun 2026 TTM: $200.02M
Menurut laporan keuangan terbaru dari Ipca Laboratories Limited, laba saat ini perusahaan adalah $200.02M. Pada tahun 2024, perusahaan memperoleh laba sebesar $100.31M, peningkatan dibandingkan laba tahun 2023 sebesar $89.11M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Ipca Laboratories Limited dari 2005 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $200.02M | 51.54% |
| 2025 | $131.99M | 31.59% |
| 2024 | $100.31M | 12.56% |
| 2023 | $89.11M | -39.31% |
| 2022 | $146.83M | -22.19% |
| 2021 | $188.69M | 92.38% |
| 2020 | $98.08M | 24.63% |
| 2019 | $78.69M | 76.36% |
| 2018 | $44.62M | 10.42% |
| 2017 | $40.41M | 135.71% |
| 2016 | $17.14M | -69.96% |
| 2015 | $57.08M | -45.77% |
| 2014 | $105.26M | 26.12% |
| 2013 | $83.46M | 16.17% |
| 2012 | $71.85M | -6.02% |
| 2011 | $76.45M | 28.95% |
| 2010 | $59.28M | 154.37% |
| 2009 | $23.31M | -46.79% |
| 2008 | $43.80M | 23.03% |
| 2007 | $35.60M | 112.82% |
| 2006 | $16.73M | -22.39% |
| 2005 | $21.55M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 782.18% |
IN
|
